PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 25, issue 12, 2007

When NICE Says No! pp. 995-996

Alan Haycox

NICE Cost-Effectiveness Appraisal of Cholinesterase Inhibitors pp. 997-1006

Denis Getsios, Kristen Migliaccio-Walle and Jaime Caro

Recombinant Factor VIIa (Eptacog Alfa) pp. 1007-1029

Katherine Lyseng-Williamson and Greg Plosker

Atorvastatin pp. 1031-1053

Greg Plosker and Katherine Lyseng-Williamson

Economic Evidence at the Local Level pp. 1055-1062

Kees Gool, Gisselle Gallego, Marion Haas, Rosalie Viney, Jane Hall and Robyn Ward

Oral Antiplatelet Therapy in Secondary Prevention of Cardiovascular Events pp. 1063-1082

Bart Heeg, Joep Damen and Ben Hout

Volume 25, issue 11, 2007

Warfarin Pharmacogenetics pp. 899-902

Dyfrig Hughes and Munir Pirmohamed

It’s Time to Choose the Study Design! pp. 903-911

Oren Shavit, Moshe Leshno, Assaf Goldberger, Amir Shmueli and Amnon Hoffman

The Cost Effectiveness of Bisphosphonates for the Prevention and Treatment of Osteoporosis pp. 913-933

Rachael Fleurence, Cynthia Iglesias and Jeanene Johnson

Cost Effectiveness of Entecavir versus Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B pp. 963-977

David Veenstra, Sean Sullivan, Lauren Clarke, Uche Iloeje, Eskinder Tafesse, Adrian Bisceglie, Kris Kowdley and Robert Gish

Volume 25, issue 10, 2007

Lessons from Trial-Based Cost-Effectiveness Analyses of Mental Health Interventions pp. 807-816

Jeffrey Hoch and Carolyn Dewa

A Comparison of the Cost Effectiveness of Pharmacotherapy or Surgery (Laparoscopic Fundoplication) in the Treatment of GORD pp. 829-841

Laura Bojke, Edward Hornby and Mark Sculpher

Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients pp. 843-862

Ya-Chen Shih, Nebiyou Bekele and Ying Xu

Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK pp. 863-879

Sorrel Wolowacz, Neil Roskell, Steven Kelly, Fiona Maciver and Chris Brand

Continuous Subcutaneous Insulin Infusion versus Multiple Daily Injections of Insulin pp. 881-897

Neale Cohen, Michael Minshall, Lyn Sharon-Nash, Katerina Zakrzewska, William Valentine and Andrew Palmer

Volume 25, issue 9, 2007

Measuring Health Preferences for Use in Cost-Utility and Cost-Benefit Analyses of Interventions in Children pp. 713-726

Lisa Prosser, James Hammitt and Ron Keren

Epidemiology and Economic Impact of Meticillin-Resistant Staphylococcus aureus pp. 751-768

Andrew Shorr

Long-Term Clopidogrel Therapy in Patients Receiving Percutaneous Coronary Intervention pp. 769-782

Bart Heeg, Ron Peters, Marc Botteman and Ben Hout

Volume 25, issue 7, 2007

A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma pp. 577-590

Ya-Chen Shih, Josephine Mauskopf and Rohit Borker

Direct and Indirect Costs Attributable to Alcohol Consumption in Germany pp. 605-618

Alexander Konnopka and Hans-Helmut König

Volume 25, issue 6, 2007

A Systematic Review of Economic Evaluation Literature in Thailand pp. 467-479

Yot Teerawattananon, Steve Russell and Miranda Mugford

Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs pp. 481-496

Theodore Darkow, Henry Henk, Simu Thomas, Weiwei Feng, Jean-Francois Baladi, George Goldberg, Alan Hatfield and Jorge Cortes

Volume 25, issue 5, 2007

Health Utilities Using the EQ-5D in Studies of Cancer pp. 365-384

A. Pickard, Caitlyn Wilke, Hsiang-Wen Lin and Andrew Lloyd

The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD) pp. 385-396

Peter Wahlqvist, Gordon Guyatt, David Armstrong, Alessio Degl’Innocenti, Diane Heels-Ansdell, Samer El-Dika, Ingela Wiklund, Carlo Fallone, Lisa Tanser, Sander Zanten, Peggy Austin, Alan Barkun, Naoki Chiba and Holger Schünemann

Costs of a Community Pharmacist-Led Medicines Management Service for Patients with Coronary Heart Disease in England pp. 397-411

Anthony Scott, Michela Tinelli and Christine Bond

Cost Effectiveness of Trastuzumab in the Adjuvant Treatment of Early Breast Cancer pp. 429-442

J. Millar and Michael Millward

Volume 25, issue 3, 2007

Do Drugs Reduce Utilisation of Other Healthcare Resources? pp. 209-221

Pierre-Yves Crémieux, Pierre Ouellette and Patrick Petit

Recombinant Erythropoietin for Chemotherapy-Related Anaemia pp. 223-237

Diego Ossa, Andrew Briggs, Emma McIntosh, Warren Cowell, Tim Littlewood and Mark Sculpher

Cost Effectiveness of an Adherence-Improving Programme in Hypertensive Patients pp. 239-251

Danielle Brunenberg, Gwenn Wetzels, Patricia Nelemans, Carmen Dirksen, Johan Severens, Henri Stoffers, Jan Schouten, Martin Prins, Peter Leeuw and Manuela Joore

Volume 25, issue 2, 2007

Measuring Preferences for Cost-Utility Analysis pp. 93-106

Christine McDonough and Anna Tosteson

Acute/Subacute Herpes Zoster pp. 155-169

Ralph Insinga, Robbin Itzler and James Pellissier

Volume 25, issue 1, 2007

Letter From the Commissioner’s Office at the US FDA pp. 1-2

John Vernon

Rates and Probabilities in Economic Modelling pp. 3-6

Rachael Fleurence and Christopher Hollenbeak

Reducing the Societal Burden of Depression pp. 7-24

Julie Donohue and Harold Pincus

Cost Effectiveness of a Pharmacy-Based Coaching Programme to Improve Adherence to Antidepressants pp. 25-37

Judith Bosmans, Oscar Brook, Hein Hout, Martine Bruijne, Hugo Nieuwenhuyse, Lex Bouter, Wim Stalman and Maurits Tulder

A Lifetime Modelled Economic Evaluation Comparing Pioglitazone and Rosiglitazone for the Treatment of Type 2 Diabetes Mellitus in the UK pp. 39-54

Dominic Tilden, Segundo Mariz, Gillies O’Bryan-Tear, Julia Bottomley and Alexander Diamantopoulos

Cost Effectiveness of Palivizumab for Respiratory Syncytial Virus Prophylaxis in High-Risk Children pp. 55-71

Mark Nuijten, Wolfgang Wittenberg and Maximilian Lebmeier

Time Preferences for Health in Northern Tanzania pp. 73-88

Bjarne Robberstad and John Cairns

Volume 24, issue 12, 2006

Do Pharmacogenomic Tests Provide Value to Policy Makers? pp. 1173-1177

Ya-Chen Shih and Lajos Pusztai

Letter From the Commissioner’s Office at the US FDA pp. 1179-1179

John Vernon

Assessing Generalisability in Model-Based Economic Evaluation Studies pp. 1181-1197

Hege Urdahl, Andrea Manca and Mark Sculpher

Generic Health-Related Quality-of-Life Assessment in Children and Adolescents pp. 1199-1220

Ulrike Ravens-Sieberer, Michael Erhart, Nora Wille, Ralf Wetzel, Jennifer Nickel and Monika Bullinger

Cost Effectiveness of Tumour Necrosis Factor-α Inhibitors as First-Line Agents in Rheumatoid Arthritis pp. 1221-1232

James Spalding and Joel Hay

Association of Co-Morbidities with Prescribing Patterns and Cost Savings pp. 1233-1248

Wei Yu, Xinhua Ren, Austin Lee, Lawrence Herz, Yu-Hui Huang and Lewis Kazis

Candesartan Cilexetil pp. 1249-1272

Greg Plosker and Susan Keam

Discounting Health Effects in Pharmacoeconomic Evaluations: Current Controversies pp. 1273-1274

Stuart Birks

The Authors’ Reply pp. 1275-1276

J. Bos, M. Postma and L. Annemans

Volume 24, issue 9, 2006

US FDA Guidance pp. 833-836

Paul Kind

Accuracy versus Transparency in Pharmacoeconomic Modelling pp. 837-844

David Eddy

The Value of Thinly Spread QALYs pp. 845-853

Duncan Mortimer

Using Discrete Choice Experiments within a Cost-Benefit Analysis Framework pp. 855-868

Emma McIntosh

Cost-of-Illness Studies pp. 869-890

Ebere Akobundu, Jing Ju, Lisa Blatt and C. Mullins

Impacts of Cost Containment Strategies on Pharmaceutical Expenditures of the National Health Insurance in Taiwan, 1996–2003 pp. 891-902

Yue-Chune Lee, Ming-Chin Yang, Yu-Tung Huang, Chien-Hsiang Liu and Sun-Bing Chen

Public Funding of Bosentan for the Treatment of Pulmonary Artery Hypertension in Australia pp. 903-915

John Wlodarczyk, Leslie Cleland, Anne Keogh, Keith McNeil, Kate Perl, Robert Weintraub and Trevor Williams

Missing Data Imputation in Quality-of-Life Assessment pp. 917-925

Ting Lin

Modelling Lifetime Metabolic Progression and Cost Effectiveness of Treatment Strategies for Type 2 Diabetes pp. 927-929

Andrew Palmer and Craig Currie

The Authors’ Reply pp. 929-935

Adrian Bagust, Marc Evans, Sophie Beale, Philip Home, Andrew Perry, Murray Stewart, Arran Shearer, Alan Martin, Lisa Hulme, Andreas Liebl, Oliver Schoeffski, Anita Goertz, Javier Ampudia-Blasco, Belen Martinez-Lage, Isabel Escolano and Gonzalo Paris

Volume 24, issue 8, 2006

Prostaglandin Analogues for the Treatment of Glaucoma and Ocular Hypertension pp. 743-750

Michelle Orme and Annabel Boler

A Comparative Review of Health-Related Quality-of-Life Measures for Use in HIV/AIDS Clinical Trials pp. 751-765

Darren Clayson, Diane Wild, Paul Quarterman, Isabelle Duprat-Lomon, Maria Kubin and Stephen Coons

Costs of Inflammatory Bowel Disease in Germany pp. 797-814

Renee Stark, Hans-Helmut König and Reiner Leidl

Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada pp. 815-830

Michele Kohli, Cheryl Attard, Annette Lam, Daniel Huse, John Cook, Chantal Bourgault, Evo Alemao, Donald Yin and Michael Marentette

Volume 24, issue 6, 2006

Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy pp. 523-535

Cornelis Boersma, Jarir Atthobari, Ron Gansevoort, Lolkje Jong- Van den Berg, Paul Jong, Dick Zeeuw, Lieven Annemans and Maarten Postma

Healthcare Rationing in Spain pp. 537-548

Rosa Rodríguez-Monguió and Fernando Villar

The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy pp. 549-558

George Carides, Shahnaz Shahinfar, Erik Dasbach, William Keane, William Gerth, Charles Alexander, William Herman and Barry Brenner

The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status pp. 559-569

Jarmo Hahl, Helena Hämäläinen, Tuula Simell and Olli Simell

Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients pp. 571-591

Peter Schädlich, Michael Kentsch, Manfred Weber, Wolfgang Kämmerer, Josef Brecht, Vijay Nadipelli and Eduard Huppertz

Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients pp. 593-607

George Dranitsaris, Mark Vincent and Mark Crowther

Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia? pp. 609-621

Lee-Yee Chong, Oh-Moh Chay and Li Shu-Chuen

Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease pp. 623-625

Nick Bosanquet and Andrew Yeates

The Authors’ Reply pp. 625-626

Colin Green, Joanna Picot, Emma Loveman, Andrea Takeda, Jo Kirby and Andrew Clegg

Volume 24, issue 4, 2006

A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy pp. 387-400

Aslam Anis, Huiying Sun, Sonia Singh, John Woolcott, Bohdan Nosyk and Marc Brisson

Volume 24, issue 3, 2006

Medicaid Preferred Drug Lists: Cost Containment and Side Effects pp. 1-3

Alvin Headen

The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003 pp. 5-25

Frank Lichtenberg

Which Physicians are Affected Most by Medicaid Preferred Drug Lists for Statins and Antihypertensives? pp. 27-40

Jonathan Ketcham and Andrew Epstein

Effects of Medicaid Access Restrictions on Statin Utilisation for Patients Treated by Physicians Practising in Poor and Minority Neighbourhoods pp. 41-53

Alvin Headen, Neal Masia and Kirsten Axelsen

Preferred Drug Lists and Medicaid Prescriptions pp. 55-63

Tamer Abdelgawad and Lisa Egbuonu-Davis

Impact of Medicaid Preferred Drug Lists on Therapeutic Adherence pp. 65-78

David Ridley and Kirsten Axelsen

Per-patient-per-month Drug Costs in Medicare Part D Protected Classes pp. 79-84

Lisa Mucha, Neal Masia and Kirsten Axelsen

Functional Impairment, Healthcare Costs and the Prevalence of Institutionalisation in Patients with Alzheimer’s Disease and Other Dementias pp. 265-280

Jerrold Hill, Howard Fillit, Simu Thomas and Sobin Chang

Quality-of-Life Valuations of Advanced Breast Cancer by New Zealand Women pp. 281-292

Richard Milne, Kathy Heaton-Brown, Paul Hansen, David Thomas, Vernon Harvey and Alison Cubitt

Volume 24, issue 2, 2006

Foreword pp. 1-3

Christopher-Paul Milne

Health Reform in the US pp. 5-14

Robert Helms

What Works and What Doesn’t Work Well in the US Healthcare System pp. 15-28

Harold Luft

What an Informed Patient Means for the Future of Healthcare pp. 29-33

Ruth Parker

The Impact of Therapeutic Reference Pricing on Innovation in Cardiovascular Medicine pp. 35-54

Desmond Sheridan and Jim Attridge

Disease Management Programmes in Germany pp. 55-57

Stefan Felder

Do Health-Related Labour Costs Weaken the Competitiveness of the Economy? pp. 59-68

Bertram Häussler, Thomas Ecker and Markus Schneider

The Impact of Incremental Innovation in Biopharmaceuticals pp. 69-86

Ernst Berndt, Iain Cockburn and Karen Grépin

Transatlantic Convergence with Respect to the Fourth Hurdle? pp. 87-94

Joshua Cohen

Political Challenges for Healthcare Reform pp. 95-99

Lawrence Brown

Lean Systems Approaches to Health Technology Assessment pp. 101-109

John Bridges

Building a Competitive Insurance System pp. 111-119

Peter Zweifel

Concluding Remarks pp. 121-122

Kenneth Kaitin

The Long-Term Cost Effectiveness of Treatments for Benign Prostatic Hyperplasia pp. 171-191

Rachael DiSantostefano, Andrea Biddle and John Lavelle

Evaluation of Non-Medical Costs Associated with Visual Impairment in Four European Countries pp. 193-205

Antoine Lafuma, Antoine Brézin, Stefania Lopatriello, Klaus Hieke, Julia Hutchinson, Viviane Mimaud and Gilles Berdeaux

Volume 24, issue 1, 2006

Simulating the Real World of Antihyperglycaemic Therapies in Type 2 Diabetes pp. 1-3

Amanda Adler

A Model of Long-term Metabolic Progression of Type 2 Diabetes Mellitus for Evaluating Treatment Strategies pp. 5-19

Adrian Bagust, Marc Evans, Sophie Beale, Philip Home, Andrew Perry and Murray Stewart

Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK pp. 21-34

Sophie Beale, Adrian Bagust, Arran Shearer, Alan Martin and Lisa Hulme

Cost-effectiveness of Rosiglitazone Oral Combination for the Treatment of Type 2 Diabetes in Germany pp. 35-48

Arran Shearer, Adrian Bagust, Andreas Liebl, Oliver Schoeffski and Anita Goertz

Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain pp. 49-59

Arran Shearer, Adrian Bagust, F. Ampudia-Blasco, Belén Martínez-Lage Álvarez, Isabel Pérez Escolano and Gonzalo París